Journal of Forensic Medicine

Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary

Publications

• Mini Review   
  Understanding the Basis for Blocking MCPggaac Haplotype Complement Activity after Atypical Hemolytic Uremic Syndrome Incidence in Three Countries of Southeastern Europe
  Author(s): Velibor Turudic*
  
  We present a series of cases involving individuals with the homozygous MCPggaac haplotype, a genetic configuration associated with an increased likelihood and severity of atypical hemolytic uremic syndrome (aHUS), particularly when combined with other high-risk aHUS mutations. Complement blockade therapy was administered at a median age of 92 months (with an interquartile range of 36 to 252 months). Prior to initiating CBT (Eculizumab), patients experienced a median of two disease relapses. These relapses transpired within an average span of 22.16 months (median of 17.5, ranging from a minimum of 8 months to a maximum of 48 months) following the initial subsequent disease onset (observed in 6 out of 8 patients). Treatment encompassed plasmapheresis/intravenous plasma exchange (PI/PEX), occasionally supplemented by renal replacement therapy (RRT). Upon the imple.. Read More»
  DOI: 10.37421/2472-1026.2023.8.213

  Abstract HTML PDF